Research & DevelopmentPharmaNews.eu - the dynamic European pharmaceutical news engine.http://www.pharmanews.eu/research-and-development2015-08-03T00:24:57ZJoomla! 1.5 - Open Source Content ManagementIMI Call for proposals with focus on Alzheimer's disease, diabetes, patient involvement2015-07-10T11:00:00Z2015-07-10T11:00:00Zhttp://www.pharmanews.eu/research-and-development/1521-imi-call-for-proposals-with-focus-on-alzheimers-disease-diabetes-patient-involvementAdministratorruslan.david@gmail.comThe Innovative Medicines Initiative (IMI) has launched its 5th Call for proposals under the IMI 2 programme. IMI 2 - Call 5 has a total budget of €95 million and features 6 topics. Of these, four focus on different aspects of Alzheimer's disease, one focuses on diabetic kidney disease, and one addresses patient input on assessments of the benefits and risks of medicines. Four topics focus on Alzheimer's disease, an area where there is an urgent need for new treatments.The Innovative Medicines Initiative (IMI) has launched its 5th Call for proposals under the IMI 2 programme. IMI 2 - Call 5 has a total budget of €95 million and features 6 topics. Of these, four focus on different aspects of Alzheimer's disease, one focuses on diabetic kidney disease, and one addresses patient input on assessments of the benefits and risks of medicines. Four topics focus on Alzheimer's disease, an area where there is an urgent need for new treatments.Vitamin C related to reduced risk of cardiovascular disease and early death2015-07-07T10:00:00Z2015-07-07T10:00:00Zhttp://www.pharmanews.eu/research-and-development/1520-vitamin-c-related-to-reduced-risk-of-cardiovascular-disease-and-early-deathAdministratorruslan.david@gmail.comNew research from the University of Copenhagen and Herlev and Gentofte Hospital shows that high vitamin C concentrations in the blood from the intake of fruit and vegetables are associated with a reduced risk of cardiovascular disease and early death. Fruit and vegetables are healthy. We all know that. And now there is yet another good reason for eating lots of it. New research from the University of Copenhagen shows that the risk of cardiovascular disease and early death falls with a high intake of fruit and vegetables, and that this may be dued to vitamin C.New research from the University of Copenhagen and Herlev and Gentofte Hospital shows that high vitamin C concentrations in the blood from the intake of fruit and vegetables are associated with a reduced risk of cardiovascular disease and early death. Fruit and vegetables are healthy. We all know that. And now there is yet another good reason for eating lots of it. New research from the University of Copenhagen shows that the risk of cardiovascular disease and early death falls with a high intake of fruit and vegetables, and that this may be dued to vitamin C.How removing a protein slows blood vessel growth in tumors2015-07-01T13:00:00Z2015-07-01T13:00:00Zhttp://www.pharmanews.eu/research-and-development/1519-how-removing-a-protein-slows-blood-vessel-growth-in-tumorsAdministratorruslan.david@gmail.comScientists from the University of Leeds and The Institute of Cancer Research, London, have discovered a new protein which triggers the growth of blood vessels in breast cancer tumours which have spread to the brain, a common location which breast cancer can spread to. Dr Georgia Mavria's team in the School of Medicine at Leeds found that by withholding the DOCK4 protein in mouse models, a particular part of the blood vessel did not form as quickly, meaning tumours grew at a slower rate.Scientists from the University of Leeds and The Institute of Cancer Research, London, have discovered a new protein which triggers the growth of blood vessels in breast cancer tumours which have spread to the brain, a common location which breast cancer can spread to. Dr Georgia Mavria's team in the School of Medicine at Leeds found that by withholding the DOCK4 protein in mouse models, a particular part of the blood vessel did not form as quickly, meaning tumours grew at a slower rate.Brain inflammation targeted in first drug discovery project from £3m Dementia Consortium2015-06-18T22:01:00Z2015-06-18T22:01:00Zhttp://www.pharmanews.eu/research-and-development/1518-brain-inflammation-targeted-in-first-drug-discovery-project-from-p3m-dementia-consortiumAdministratorruslan.david@gmail.comFunding worth nearly half a million pounds will unite academics at the University of Southampton with drug discovery experts at the medical research charity MRC Technology, to target the immune system in the hunt for new treatments for Alzheimer's disease. The work is the first to be funded by the Dementia Consortium - a unique £3m drug discovery collaboration between Alzheimer's Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly. By uniting expertise, this focused cash injection will bridge the gap between academic research and the pharmaceutical industry in the search for new drugs to slow the development of Alzheimer's.Funding worth nearly half a million pounds will unite academics at the University of Southampton with drug discovery experts at the medical research charity MRC Technology, to target the immune system in the hunt for new treatments for Alzheimer's disease. The work is the first to be funded by the Dementia Consortium - a unique £3m drug discovery collaboration between Alzheimer's Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly. By uniting expertise, this focused cash injection will bridge the gap between academic research and the pharmaceutical industry in the search for new drugs to slow the development of Alzheimer's.Restoring natural immunity against cancers2015-06-17T13:00:00Z2015-06-17T13:00:00Zhttp://www.pharmanews.eu/research-and-development/1517-restoring-natural-immunity-against-cancersAdministratorruslan.david@gmail.comScientists at the Institut Pasteur and Inserm have successfully increased the infiltration of immune cells into tumors, thus inducing the immune system to block tumor growth. In an article published in Nature Immunology, the scientists show that, in combination with existing immunotherapies, this process efficiently destroys cancer cells. Chemokines are small molecules that can attract immune cells towards inflammatory tissues, acting for example during tumor development or upon infection, in order to support migration of lymphocytes into diseased tissues. However, these molecules may be degraded by enzymes, a process that limits the influx of immune cells.Scientists at the Institut Pasteur and Inserm have successfully increased the infiltration of immune cells into tumors, thus inducing the immune system to block tumor growth. In an article published in Nature Immunology, the scientists show that, in combination with existing immunotherapies, this process efficiently destroys cancer cells. Chemokines are small molecules that can attract immune cells towards inflammatory tissues, acting for example during tumor development or upon infection, in order to support migration of lymphocytes into diseased tissues. However, these molecules may be degraded by enzymes, a process that limits the influx of immune cells.New drug can clear all psoriasis symptoms2015-06-11T11:00:00Z2015-06-11T11:00:00Zhttp://www.pharmanews.eu/research-and-development/1516-new-drug-can-clear-all-psoriasis-symptomsAdministratorruslan.david@gmail.comA University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement. The research tested 2,500 people with psoriasis. Half were given a new drug - ixekizumab - either once every two or four weeks. The other half were given a placebo or a widely used drug for psoriasis called etanercept. The ixekizumab groups showed quick and extensive improvements in their condition, outperforming the groups on placebo or etanercept. Around half of these patients showed improvement as early as week four of the trial and up to 71% had shown a high level of improvement, as measured using a scale called the Psoriasis Area and Severity Index, by week 12.A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement. The research tested 2,500 people with psoriasis. Half were given a new drug - ixekizumab - either once every two or four weeks. The other half were given a placebo or a widely used drug for psoriasis called etanercept. The ixekizumab groups showed quick and extensive improvements in their condition, outperforming the groups on placebo or etanercept. Around half of these patients showed improvement as early as week four of the trial and up to 71% had shown a high level of improvement, as measured using a scale called the Psoriasis Area and Severity Index, by week 12.viomedo Provides Access to Innovative Treatment Methods2015-05-18T10:00:00Z2015-05-18T10:00:00Zhttp://www.pharmanews.eu/research-and-development/1514-viomedo-provides-access-to-innovative-treatment-methodsAdministratorruslan.david@gmail.comInformation overload is a common and significant problem with most existing clinical trial search platforms or applications. viomedo makes clinical trial information easily accessible to everybody based on a variety of criteria and by following patient-centric approaches. So far, viomedo online platform aggregates about close to 2.000 clinical trials conducted in Germany. viomedo's founder Alexander Puschilov mentioned: "We are convinced, that everybody has the right to get the best possible therapy! This is why we’ve built viomedo to help patients discover and benefit from innovative treatment methods that were previously accessible only to a few lucky patients."Information overload is a common and significant problem with most existing clinical trial search platforms or applications. viomedo makes clinical trial information easily accessible to everybody based on a variety of criteria and by following patient-centric approaches. So far, viomedo online platform aggregates about close to 2.000 clinical trials conducted in Germany. viomedo's founder Alexander Puschilov mentioned: "We are convinced, that everybody has the right to get the best possible therapy! This is why we’ve built viomedo to help patients discover and benefit from innovative treatment methods that were previously accessible only to a few lucky patients."Join the Largest eHealth Gathering of the Year2015-05-01T10:00:00Z2015-05-01T10:00:00Zhttp://www.pharmanews.eu/research-and-development/1512-join-the-largest-ehealth-gathering-of-the-yearAdministratorruslan.david@gmail.com<b>11 - 13 May 2015</b>, Riga, Latvia.<br />
Part of the European eHealth Community? Don't miss out on the event of the year. Join eHealth Week 2015 and embark upon three full days of exchanging knowledge and sharing best practices amongst health IT representatives of the highest level from the 28 EU Member States. Featuring the hottest topics from the future of mHealth to patient engagement, eHealth Week 2015 is simply the must-attend event of the year. Taking place during the Latvian Presidency of the Council of the European Union, eHealth Week 2015 comprises of two main events: the High Level eHealth Conference organised by the Latvian Ministry of Health and the Latvian Presidency of the Council of the European Union and WoHIT (World of Health IT Conference & Exhibition) organised by HIMSS Europe.<b>11 - 13 May 2015</b>, Riga, Latvia.<br />
Part of the European eHealth Community? Don't miss out on the event of the year. Join eHealth Week 2015 and embark upon three full days of exchanging knowledge and sharing best practices amongst health IT representatives of the highest level from the 28 EU Member States. Featuring the hottest topics from the future of mHealth to patient engagement, eHealth Week 2015 is simply the must-attend event of the year. Taking place during the Latvian Presidency of the Council of the European Union, eHealth Week 2015 comprises of two main events: the High Level eHealth Conference organised by the Latvian Ministry of Health and the Latvian Presidency of the Council of the European Union and WoHIT (World of Health IT Conference & Exhibition) organised by HIMSS Europe.Pharmaceutical industry regulation undermines NICE drugs appraisal work2015-04-29T12:00:00Z2015-04-29T12:00:00Zhttp://www.pharmanews.eu/research-and-development/1511-pharmaceutical-industry-regulation-undermines-nice-drugs-appraisal-workAdministratorruslan.david@gmail.comGovernment policies that support UK pharmaceutical science and enhance export income are costing the NHS millions and undermine the National Institute for Health and Care Excellence. In an essay published today by the Journal of the Royal Society of Medicine, health economists Professor Alan Maynard and Professor Karen Bloor describe an inflationary regulatory system that lacks accountability, is not evidence-based and subverts the efficiency of the technology appraisal work carried out by NICE, a target of pharmaceutical industry hostility since it was established in 1999.Government policies that support UK pharmaceutical science and enhance export income are costing the NHS millions and undermine the National Institute for Health and Care Excellence. In an essay published today by the Journal of the Royal Society of Medicine, health economists Professor Alan Maynard and Professor Karen Bloor describe an inflationary regulatory system that lacks accountability, is not evidence-based and subverts the efficiency of the technology appraisal work carried out by NICE, a target of pharmaceutical industry hostility since it was established in 1999.Inaccurate reporting jeopardizing clinical trials2015-04-27T07:00:00Z2015-04-27T07:00:00Zhttp://www.pharmanews.eu/research-and-development/1509-inaccurate-reporting-jeopardizing-clinical-trialsAdministratorruslan.david@gmail.comThe team led by Dr Sheena Cruickshank of the Faculty of Life Sciences and Professor Andy Brass from the School of Computer Science (University of Manchester) analysed 58 papers on research into inflammatory bowel disease published between 2000 and 2014. They found a wide variety in how methods were reported and that vital information about experiments were missing, meaning they couldn't be accurately reproduced in animal or human models. In several instances the gender of the animal used wasn't recorded which can have a bearing on the result as female mice have a stronger immune response to males. How the animals were housed will also impact on the results in experiments about the gut.The team led by Dr Sheena Cruickshank of the Faculty of Life Sciences and Professor Andy Brass from the School of Computer Science (University of Manchester) analysed 58 papers on research into inflammatory bowel disease published between 2000 and 2014. They found a wide variety in how methods were reported and that vital information about experiments were missing, meaning they couldn't be accurately reproduced in animal or human models. In several instances the gender of the animal used wasn't recorded which can have a bearing on the result as female mice have a stronger immune response to males. How the animals were housed will also impact on the results in experiments about the gut.